Early adoption of Collagen/ORC therapies improves clinical outcomes in both venous leg ulcers and diabetic foot ulcers.

Breda Cullen, Molly Gibson, Lorraine Nisbet
Systagenix, Gatwick, UK

OBJECTIVE

To examine the effects on efficacy of early adoption of Collagen/ORC therapies on diabetic foot ulcers and venous leg ulcers.

EXISTING EVIDENCE

Randomised controlled trials have shown Collagen/ORC and Collagen/ORC/Silver to be more effective than control treatments on both venous leg ulcers and diabetic foot ulcers.

- Collagen/ORC therapy has been proven to be more effective than control therapy.
- However, there are some wounds that do not respond to therapy.
- Could earlier treatment improve the effectiveness of Collagen/ORC or Collagen/ORC/Silver?

How to Increase the Number of Responders?

A prospective clinical study showed that Collagen/ORC and Collagen/ORC/Silver are more effective when used early:

- Therefore, results from 3 studies have been combined to determine the effect of early treatment of Collagen/ORC on venous leg ulcers and diabetic foot ulcers.

CLINICAL STUDIES

<table>
<thead>
<tr>
<th>Wound Type</th>
<th>Treatment</th>
<th>Patient number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic Foot Ulcers²</td>
<td>Collagen/ORC/Silver</td>
<td>Week 4 n=24</td>
</tr>
<tr>
<td>Venous leg ulcers²</td>
<td>Collagen/ORC/Silver or Collagen/ORC (randomised 1:1)</td>
<td>Week 12 n=23</td>
</tr>
<tr>
<td>Venous leg ulcers³</td>
<td>Collagen/ORC/Silver</td>
<td>Week 4 n=56</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Week 12 n=50</td>
</tr>
</tbody>
</table>

CLINICAL ENDPOINTS

- Responders were defined as 30% (venous leg ulcers) or 50% (diabetic foot ulcers) reduction in wound area by Week 4 of the study. Research has shown this measure to be a good predictor of wound healing.
- Healing: 100% epithelialisation by week 12.

CONCLUSIONS

- Randomised controlled trials have shown that Collagen/ORC therapies are more effective than standard care.
- The efficacy of these therapies can be further improved by more appropriate usage.
- Early adoption of Collagen/ORC and Collagen/ORC/Silver improves clinical outcome; wounds treated within the first 6 months showed a 73% healing rate.
- PROMOGRAIN® and PROMOGRAIN PRISMA® are the only Collagen/ORC dressings available.

ABSTRACT

Introduction: This multi-centre study of venous leg ulcers and diabetic foot ulcers was designed to investigate prognostic factors predictive of response to Collagen/ORC and Collagen/ORC/Silver treatment.

Methods: Diabetic foot ulcers and venous leg ulcers were treated with Collagen/ORC or Collagen/ORC/Silver for up to 12 weeks and wound area was measured on a weekly basis. In this study we used 2 outcome measures: response to treatment, and complete healing. Response to treatment was based on percentage reduction after 4 weeks of treatment and healing at week 12. Diabetic foot ulcers achieving at least 50% reduction in wound area over the first 4 weeks, or venous leg ulcers showing at least 30% reduction in wound area over the first 4 weeks were classed as responders, wounds not achieving this percentage reduction were classed as non-responders. Healing was defined as 100% epithelialisation.

Results: Week 4 data was available for 95 patients, but due to 8 patient withdrawals there were 87 patients available for week 12 analysis. 24 patients had diabetic foot ulcers, all of which were treated with Collagen/ORC/Silver and 71 patients had venous leg ulcers, which were treated with either Collagen/ORC or Collagen/ORC/Silver. The overall rate of responders was 65% (62/95), which is increased to 79% (42/53) if wounds older than 6 months are excluded. 53% (46/87) of wounds healed by week 12 of the study. By restricting the population to wounds older than 6 months duration or less, the healing rate increased to 73% (35/48).

Conclusion: This study has shown that early treatment of chronic wounds with Collagen/ORC or Collagen/ORC/Silver leads to increased rates of healing. In the first 6 months of a wound, the ability to heal is greatest with the use of advanced treatments such as Collagen/ORC with a healing rate of 73%. Early adoption of these advanced therapies such as Collagen/ORC and Collagen/ORC/Silver for both venous leg ulcers and diabetic foot ulcers has been shown here to improve clinical outcomes.

73% of Wounds ≤6 months old healed

<table>
<thead>
<tr>
<th>Wound duration at baseline</th>
<th>% wounds healed</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤6 months</td>
<td>73%</td>
</tr>
<tr>
<td>≤1 year</td>
<td>64%</td>
</tr>
<tr>
<td>≤2 years</td>
<td>56%</td>
</tr>
<tr>
<td>Total</td>
<td>53%</td>
</tr>
</tbody>
</table>

References